RU96108803A - METHOD FOR PROCESSING A MEDICINAL PRODUCT, DEVICE AND ITS APPLICATION, Agglomerates - Google Patents

METHOD FOR PROCESSING A MEDICINAL PRODUCT, DEVICE AND ITS APPLICATION, Agglomerates

Info

Publication number
RU96108803A
RU96108803A RU96108803/14A RU96108803A RU96108803A RU 96108803 A RU96108803 A RU 96108803A RU 96108803/14 A RU96108803/14 A RU 96108803/14A RU 96108803 A RU96108803 A RU 96108803A RU 96108803 A RU96108803 A RU 96108803A
Authority
RU
Russia
Prior art keywords
agglomerates
size
spheronization
additional
paragraphs
Prior art date
Application number
RU96108803/14A
Other languages
Russian (ru)
Other versions
RU2170082C2 (en
Inventor
Трофаст Эва
Фальк Йохан
Original Assignee
Астра Актиеболаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9303214A external-priority patent/SE9303214D0/en
Priority claimed from SE9304271A external-priority patent/SE9304271D0/en
Application filed by Астра Актиеболаг filed Critical Астра Актиеболаг
Priority claimed from US08/317,033 external-priority patent/US5551489A/en
Publication of RU96108803A publication Critical patent/RU96108803A/en
Application granted granted Critical
Publication of RU2170082C2 publication Critical patent/RU2170082C2/en

Links

Claims (19)

1. Способ обработки тонкодиспергированного порошкообразного лекарственного средства, имеющего размер первичной частицы менее чем 10 мкм и обладающего низкой текучестью, для образования контролируемым способом агломератов или шариков, которые свободно текут и которые способны разрушаться с образованием тонкодиспергированного лекарственного средства, включающий стадии
а) агломерации порошкообразного лекарственного средства, имеющего размер частиц менее чем 10 мкм вещества, путем подачи вещества в шнековый питатель, прохождения вещества через шнековый питатель с получением агломератов,
b) сферонизации полученных агломератов для того, чтобы обеспечить агломераты, которые более сферичны, более плотные и более компактны, чем агломераты, получаемые в агломерационном процессе в шнековом питателе,
с) классификации по размерам агломератов для получения конечного продукта однородного размера.
1. A method of treating a finely dispersed powdered drug having a primary particle size of less than 10 μm and having low fluidity to form agglomerates or balls that flow freely and which are capable of breaking down into a finely divided drug, in a controlled manner, comprising the steps of
a) agglomeration of a powdered drug having a particle size of less than 10 μm of a substance by feeding the substance to the screw feeder, passing the substance through the screw feeder to obtain agglomerates,
b) spheronization of the obtained agglomerates in order to provide agglomerates that are more spherical, denser and more compact than the agglomerates obtained in the agglomeration process in a screw feeder,
c) size classification of agglomerates to obtain a final product of uniform size.
2. Способ по п.1, отличающийся тем, что для сферонизации агломератов, получающихся в результате агломерации, используют наклонный гранулирующий контейнер предпочтительно с одним или более скребками. 2. The method according to claim 1, characterized in that for the spheronization of agglomerates resulting from agglomeration, an inclined granulating container is used, preferably with one or more scrapers. 3. Способ по п. 1 или 2, отличающийся тем, что для классификации по размерам образующихся агломератов используют сито. 3. The method according to p. 1 or 2, characterized in that for the classification by size of the resulting agglomerates using a sieve. 4. Способ по п. 1, отличающийся тем, что размер частиц тонкодиспергированного порошкообразного лекарственного средства меньше чем 10 мкм и что размер агломератов после процесса агломерации составляет менее чем или равен 2 мм. 4. The method according to p. 1, characterized in that the particle size of the finely divided powdered drug is less than 10 microns and that the size of the agglomerates after the agglomeration process is less than or equal to 2 mm 5. Способ по п.1, отличающийся тем, что тонкодиспергированное порошкообразное лекарственное средство загружают в шнековый питатель, включающий двояковогнутые шнеки, имеющие шаг шнеков около 2 - 20 мм, предпочтительно 5 - 15 мм. 5. The method according to claim 1, characterized in that the finely dispersed powdered drug is loaded into a screw feeder including biconcave screws having a screw pitch of about 2-20 mm, preferably 5-15 mm. 6. Способ по пп. 1 - 5, отличающийся тем, что он после агломерации в шнековом питателе дополнительно включает стадию классификации по размерам агломерированного порошка с получением агломератов однородного размера. 6. The method according to PP. 1 to 5, characterized in that after agglomeration in a screw feeder, it further includes a step of size classification of the agglomerated powder to obtain agglomerates of uniform size. 7. Способ по п. 6, отличающийся тем, что он после сферонизации включает дополнительную стадию классификации по размерам и дополнительную стадию сферонизации. 7. The method according to p. 6, characterized in that after spheronization it includes an additional stage of classification by size and an additional stage of spheronization. 8. Способ по п.7, отличающийся тем, что для дополнительной классификации по размерам используют дополнительное сито, и для сферонизации используют дополнительный наклонный гранулирующий контейнер предпочтительно с одним или более скребками. 8. The method according to claim 7, characterized in that for an additional classification by size an additional sieve is used, and for spheronization an additional inclined granulating container is used, preferably with one or more scrapers. 9. Способ по любому из предшествующих пунктов, отличающийся тем, что окружная скорость гранулирующего контейнера предпочтительно составляет 0,5 - 1,0 м/с. 9. The method according to any one of the preceding paragraphs, characterized in that the peripheral speed of the granulating container is preferably 0.5 to 1.0 m / s. 10. Способ по любому из предшествующих пунктов, отличающийся тем, что время сферонизации предпочтительно составляет 2 - 20 мин. 10. The method according to any one of the preceding paragraphs, characterized in that the spheronization time is preferably 2 to 20 minutes 11. Устройство для обработки тонкодиспергированного порошкообразного лекарственного средства, имеющего размер частиц менее чем 10 мкм и низкую текучесть, которое контролируемым способом заставляет порошкообразное лекарственное средство образовывать маленькие непрочные агломераты или шарики, которые свободно текут и которые способны разрушаться с образованием тонкодиспергированного лекарственного средства, и это устройство включает шнековый питатель (6, 6') с по крайней мере двумя связанными друг с другом шнеками (8а, 8b), которые вращаются, сферонизирующее устройство для сферонизации образующихся агломератов и устройство для классификации по размерам для разделения агломератов по размерам, чтобы получить конечный продукт однородного размера. 11. A device for treating a finely dispersed powdered drug having a particle size of less than 10 microns and low fluidity, which in a controlled manner causes the powdered drug to form small fragile agglomerates or balls that flow freely and which are capable of breaking down to form a finely dispersed drug the device includes a screw feeder (6, 6 ') with at least two connected screws (8a, 8b) that rotate a spheronizing device for spheronizing the resulting agglomerates and a size classification device for separating the agglomerates in size to obtain a final product of uniform size. 12. Устройство по п.11, отличающееся тем, что для сферонизации агломератов, образующихся в результате агломерации, используют наклонный гранулирующий контейнер (16, 16'), предпочтительно с одним или более скребками (18). 12. The device according to claim 11, characterized in that for the spheronization of agglomerates resulting from agglomeration, an inclined granulating container (16, 16 ') is used, preferably with one or more scrapers (18). 13. Устройство по п.11 или 12, отличающееся тем, что для классификации по размерам образующихся агломератов используют сито (20, 20'). 13. The device according to claim 11 or 12, characterized in that a sieve (20, 20 ') is used to classify by size the resulting agglomerates. 14. Устройство по п.11, отличающееся тем, что шнековый питатель (6, 6') включает двояковогнутые (Тwin-сoncave ) шнеки (8а, 8b), имеющие шаг шнеков около 2 - 20 мм, предпочтительно 5 - 15 мм. 14. The device according to claim 11, characterized in that the screw feeder (6, 6 ') includes biconcave (Twin-concave) screws (8a, 8b) having a screw pitch of about 2 to 20 mm, preferably 5 to 15 mm. 15. Устройство по п.11 или 12, отличающееся тем, что оно включает первое дополнительное сито (22), второе дополнительное сито (24) и первый дополнительный наклонный гранулирующий контейнер (26) предпочтительно с одним или более скребками. 15. The device according to claim 11 or 12, characterized in that it includes a first additional sieve (22), a second additional sieve (24) and a first additional inclined granulating container (26), preferably with one or more scrapers. 16. Устройство по пп. 11 - 15, отличающееся тем, что отверстия в ситах имеют размер между 0,2 - 2,0 мм, предпочтительно между 0,3 - 1,0 мм. 16. The device according to paragraphs. 11 to 15, characterized in that the openings in the sieves have a size between 0.2 - 2.0 mm, preferably between 0.3 - 1.0 mm. 17. Применение устройства по любому из пп. 11 - 16 для осуществления способа по любому из пп. 1 - 10. 17. The use of the device according to any one of paragraphs. 11 to 16 for implementing the method according to any one of paragraphs. 1 - 10. 18. Агломераты, полученные по способу, описанному в пп. 1 - 10 с использованием устройства, описанного по пп. 11 - 16, для использования в ингаляторе с сухим порошком, приводимым в действие дыханием. 18. Agglomerates obtained by the method described in paragraphs. 1 to 10 using the device described in paragraphs. 11 to 16, for use in an inhaler with a dry powder, breath-actuated. 19. Агломераты по п.18, в котором ингалятор представляет собой ТurbuhalerR.19. Agglomerates according to claim 18, wherein the inhaler is Turbuhaler R.
RU96108803/14A 1993-10-01 1994-09-29 Medical preparation and method and device for processing and producing the preparation RU2170082C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9303214A SE9303214D0 (en) 1993-10-01 1993-10-01 Process I
SE9304271A SE9304271D0 (en) 1993-12-22 1993-12-22 Process I
SE9303214-2 1993-12-22
SE9304271-1 1993-12-22
US08/317,033 US5551489A (en) 1993-10-01 1994-10-03 Agglomeration of finely divided powders

Publications (2)

Publication Number Publication Date
RU96108803A true RU96108803A (en) 1998-06-10
RU2170082C2 RU2170082C2 (en) 2001-07-10

Family

ID=27355730

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96108803/14A RU2170082C2 (en) 1993-10-01 1994-09-29 Medical preparation and method and device for processing and producing the preparation

Country Status (23)

Country Link
US (1) US5551489A (en)
EP (1) EP0721331B1 (en)
JP (1) JP3732508B2 (en)
CN (1) CN1110300C (en)
AT (1) ATE209903T1 (en)
AU (1) AU679789B2 (en)
BR (1) BR9407686A (en)
CZ (1) CZ289214B6 (en)
DE (1) DE69429357T2 (en)
DK (1) DK0721331T3 (en)
EG (1) EG20677A (en)
ES (1) ES2166786T3 (en)
FI (1) FI116364B (en)
HU (1) HU222355B1 (en)
IL (1) IL111080A (en)
NO (1) NO314836B1 (en)
NZ (1) NZ274277A (en)
PL (1) PL175564B1 (en)
PT (1) PT721331E (en)
RU (1) RU2170082C2 (en)
SG (1) SG48049A1 (en)
SK (1) SK283569B6 (en)
WO (1) WO1995009615A1 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
SE9700134D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700136D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19522899C1 (en) * 1995-06-23 1996-12-19 Hexal Pharmaforschung Gmbh Process for the continuous sintering of a granulate
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
SE9700135D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998041193A1 (en) * 1997-03-20 1998-09-24 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
EP1075278A1 (en) * 1998-01-13 2001-02-14 AstraZeneca UK Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7304750B2 (en) 1999-12-17 2007-12-04 Nektar Therapeutics Systems and methods for non-destructive mass sensing
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
EP1345629A2 (en) 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
ES2275866T3 (en) 2001-02-14 2007-06-16 Tibotec Pharmaceuticals Ltd. 2- (AMINOSUSTITUDED) -BENZOTIAZOL-SULFONAMIDES OF SPACIOUS INHIBITING SPIRITS OF THE HIV PROTEASE.
PL367084A1 (en) 2001-04-09 2005-02-21 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
CN100549007C (en) 2001-05-11 2009-10-14 泰博特克药品有限公司 Broadspectrum 2-amino-benzo azoles sulfonamide HIV protease inhibitors
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
PT1455755E (en) * 2001-11-20 2013-06-18 Civitas Therapeutics Inc Improved particulate compositions for pulmonary delivery
MY138657A (en) 2001-12-21 2009-07-31 Tibotec Pharm Ltd broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
WO2003097616A1 (en) 2002-05-17 2003-11-27 Tibotec Pharmaceuticals Ltd Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
AU2003262574B2 (en) 2002-08-14 2009-07-09 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
NZ544980A (en) 2003-09-11 2009-02-28 Tibotec Pharm Ltd Entry inhibitors of the HIV virus
SE528121C2 (en) * 2004-03-29 2006-09-05 Mederio Ag Preparation of dry powder for pre-measured DPI
AR048650A1 (en) 2004-05-04 2006-05-10 Tibotec Pharm Ltd DERIVATIVES OF (1,10B-DIHIDRO-2- (AMINOCARBONIL-PHENYL) -5H-PIRAZOLO [1,5 C] [1,3] BENZOXAZIN-5-IL) METHANONE PHENYL AS INHIBITORS OF HIV VIRAL REPLICATION
US7378441B2 (en) 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
AR049340A1 (en) 2004-05-17 2006-07-19 Tibotec Pharm Ltd 1- HETEROCICLIL - L, 5- DIHYDR- PIRIDO (3,2-B) INDOL - 2- ONAS
TW200613307A (en) 2004-05-17 2006-05-01 Tibotec Pharm Ltd 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones
ES2351702T3 (en) 2004-05-17 2011-02-09 Tibotec Pharmaceuticals 1-PHENYL-1,5-DIHIDRO-PIRIDO [3,2-B] INDOL-2-ONAS 6,7,8,9-USEFUL SUBSTITUTES AS ANTI-INFECTIVE PHARMACEUTICAL AGENTS.
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2007045496A1 (en) 2005-10-21 2007-04-26 Universiteit Antwerpen Novel urokinase inhibitors
RU2008143342A (en) 2006-04-03 2010-05-10 Тиботек Фармасьютикалз Лтд. (Ie) 3, 4-dihydroimidazo (4, 5-B) pyridine-5-ones inhibiting HIV (HIV)
DE102007049931A1 (en) 2007-10-18 2009-04-23 Pharmatech Gmbh Apparatus and method for the continuous production of spherical powder agglomerates
EP2116236A1 (en) 2008-04-21 2009-11-11 Université de Mons-Hainaut Bisbenzamidine derivatives for use as antioxidant
MX2011011122A (en) * 2009-04-24 2011-11-04 Schering Corp Agglomerate formulations including active pharmaceutical agents with targeted particle sizes.
MX2012010174A (en) 2010-03-02 2012-11-30 Amakem Nv Heterocyclic amides as rock inhibitors.
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
GB201108225D0 (en) 2011-05-17 2011-06-29 Amakem Nv Novel KBC inhibitors
GB201113689D0 (en) 2011-08-09 2011-09-21 Amakem Nv Novel PDE4 inhibitors
GB201114854D0 (en) 2011-08-29 2011-10-12 Amakem Nv Novel rock inhibitors
US9079858B2 (en) 2011-08-31 2015-07-14 Amakem Nv Rock kinase inhibitors
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
HUE029728T2 (en) 2011-09-30 2017-03-28 Ipsen Pharma Sas Macrocyclic lrrk2 kinase inhibitors
PL2810198T3 (en) 2012-01-30 2024-01-22 Universiteit Gent Anti-invasive compounds
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
CA2906262A1 (en) 2013-03-15 2014-09-18 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
WO2015150337A1 (en) 2014-04-01 2015-10-08 Amakem Nv Lim kinase inhibitors
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
US10023602B2 (en) 2014-07-08 2018-07-17 Universiteit Gent Hamamelitannin analogues and uses thereof
ES2717510T3 (en) 2014-09-17 2019-06-21 Oncodesign Sa Macrocyclic kinase inhibitors LRRK2
BR112017004035B1 (en) 2014-09-17 2023-11-14 Oncodesign Precision Medicine (OPM) MACROCYCLIC RIP2 KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS
WO2016083490A1 (en) 2014-11-27 2016-06-02 Remynd Nv Compounds for the treatment of amyloid-associated diseases
WO2016146651A1 (en) 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
WO2017146994A1 (en) * 2016-02-24 2017-08-31 Merck Sharp & Dohme Corp. Controlled agglomeration of micronized drug or drug-excipient mixtures
WO2017157882A1 (en) 2016-03-14 2017-09-21 Université Catholique de Louvain Serine biosynthetic pathway inhibitors
WO2018065387A1 (en) 2016-10-04 2018-04-12 Universiteit Gent Novel hamamelitannin analogues and uses thereof
EP3544952A1 (en) 2016-11-24 2019-10-02 Universiteit Antwerpen Halogenated benzotropolones as atg4b inhibitors
EP3573608A1 (en) 2017-01-30 2019-12-04 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
DK3621963T3 (en) 2017-05-11 2024-04-15 Remynd N V Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
WO2019193091A1 (en) 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CN114206864A (en) 2019-05-14 2022-03-18 苏州四体康宸医药科技有限公司 Quinazoline-2, 4-dione derivatives as PARP inhibitors
WO2022157381A1 (en) 2021-01-25 2022-07-28 Universiteit Hasselt Phloretin for use in the treatment of neurodegenerative and demyelinating diseases
WO2023021132A1 (en) 2021-08-18 2023-02-23 Katholieke Universiteit Leuven 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
WO2023046900A1 (en) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Ribonucleoside analogues against -sars-cov-2
WO2023241799A1 (en) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols for use in the treatment of retroviral infections

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2609150A (en) * 1949-11-05 1952-09-02 Union Carbide & Carbon Corp Mechanical pulverization of refrigerated plastics
NL128302C (en) * 1960-03-25 1900-01-01
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US3802822A (en) * 1972-03-01 1974-04-09 Mars Mineral Corp Pelletizer
GB1520247A (en) * 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1569611A (en) * 1976-01-23 1980-06-18 Fisons Ltd Pelletised or granular medicament formulation
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4161526A (en) * 1978-07-20 1979-07-17 Sterling Drug Inc. Zinc salt prevention or removal of discoloration in pyrithione, pyrithione salt and dipyrithione compositions
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
US4688610A (en) * 1985-03-19 1987-08-25 Spiral Systems Inc. Apparatus for dispensing particulate agglomerating solids
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
GB8606762D0 (en) * 1986-03-19 1986-04-23 Boots Co Plc Therapeutic agents
JPS63116732A (en) * 1986-11-06 1988-05-21 Fukae Kogyo Kk Apparatus for treating particulate material
GB8711005D0 (en) * 1987-05-09 1987-06-10 British Petroleum Co Plc Chemical process
EP0441740B1 (en) * 1990-01-29 1993-09-22 Ciba-Geigy Ag Method and device for dosing a fine particles powder
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
US5394868A (en) * 1992-06-25 1995-03-07 Schering Corporation Inhalation device for powdered medicaments

Similar Documents

Publication Publication Date Title
RU96108803A (en) METHOD FOR PROCESSING A MEDICINAL PRODUCT, DEVICE AND ITS APPLICATION, Agglomerates
RU2170082C2 (en) Medical preparation and method and device for processing and producing the preparation
RU96108939A (en) METHOD FOR TREATMENT OF MEDICINE, DEVICE AND ITS APPLICATION, SUSPENSIONS
EP0721332B1 (en) Process ii
KR100347496B1 (en) Method and apparatus for producing aggregates
RU2170537C2 (en) Recovered tobacco processing method
JPS60122058A (en) Crushing method
TH17292A (en) Fine Powder Bundles
SA94150252B1 (en) Method and device for agglomerating powders